



PRESS RELEASE

Complix receives EUR 1.6 million IWT grant to accelerate development of therapeutic Alfabodies™

Hasselt, December 21, 2010 – Complix announces that it has been awarded a EUR 1.6 million grant (approximately USD 2.1 million) from the Flanders government through IWT (Agency for Innovation by Science and Technology in Flanders). In June of this year Complix already raised EUR 5 million in equity financing to fund its preclinical development programs based on therapeutic Alfabodies™. The present funding by IWT, which covers a period of 2 years, will allow Complix to accelerate the development of its lead Alfabody™ product for treatment of autoimmune diseases.

Alfabodies™ are a novel class of small, highly stable proteins with unique structural and functional properties, that bind with high selectivity to disease-associated target molecules. Complix is focusing on the development of Alfabody™ based therapies for treatment of autoimmune and viral diseases.

Commenting on this IWT funding, Dr Mark Vaeck, CEO of Complix, stated: *“We are delighted with this significant funding from IWT, which is a clear endorsement of the innovative character and the commercial potential of our Alfabody™ platform.”*

Dr Ignace Lasters, CSO of Complix, added: *“Alfabodies™ are a promising new class of protein therapeutics with significant and broad applications in various therapeutic areas. This IWT funding will help us to progress rapidly towards clinical proof of concept with our lead Alfabody™ product in a first disease indication.”*

Complix was founded two years ago and is focused on the discovery and development of next generation protein drugs based on “Alfabodies™”, a novel class of biopharmaceuticals with superior therapeutic potential.



Notes for the editor:

About Complix

Complix is a biopharmaceutical company focused on the discovery and development of novel therapeutics based on its proprietary Alphabody™ platform. Alphabodies™ represent a novel class of biopharmaceuticals that offer significant competitive advantages over existing protein based therapies. Alphabodies™ can bind with high affinity to a wide range of disease targets, and can address certain target types that are not easily accessible by antibodies or other protein scaffolds. Alphabodies™ are extremely stable as compared to other biopharmaceuticals, and can be applied via alternative, non-injectable routes of administration. Complix's initial R&D focus is on the development of novel Alphabody™ based therapies for autoimmune - and infectious diseases. Through the filing of several broad patent applications Complix has established a strong intellectual property position on the Alphabody™ technology. Because the Alphabody™ structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims.

Complix was created in 2008 with seed capital from Gemma Frisius Fund, Baekeland Fund, Vinnof and Trustcapital. In June of 2010 Complix raised EUR 5 million through a Series A equity financing round, co-led by Vesalius Biocapital and LRM, and with CRP-Santé from Luxembourg also participating. The Company is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. Complix has established a fully owned subsidiary in Luxembourg, which is focused on the discovery of novel anti-viral therapeutics, and has a strategic alliance with the public research institute CRP-Santé.

www.complix.com

For further information please contact:

Complix NV

Dr. Mark Vaeck, CEO

Tel. +32 9 241 57 15

info@complix.com